Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVEREST: upper target everolimus randomized study in de novo renal transplant recipients
2005-000864-16Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in kidney allograft rejection (2 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of everolimus plus Neoral regimens and Efficacy in prevention of renal transplant rejection. Started Dec 2005; status: completed.
02
Drugs
everolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2005-000864-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000864-16.